Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type

Joungyoun Kim, Hyeong-Seop Kim, Woojung Yang, Jae-woo Lee and Hee-Taik Kang
Additional contact information
Joungyoun Kim: Department of Information & Statistics, Chungbuk National University, Cheongju 28644, Korea
Hyeong-Seop Kim: Department of Information & Statistics, Chungbuk National University, Cheongju 28644, Korea
Woojung Yang: Department of Family Medicine, Chungbuk National University Hospital, Cheongju 28644, Korea
Jae-woo Lee: Department of Family Medicine, Chungbuk National University Hospital, Cheongju 28644, Korea
Hee-Taik Kang: Department of Family Medicine, Chungbuk National University Hospital, Cheongju 28644, Korea

IJERPH, 2020, vol. 17, issue 17, 1-12

Abstract: (1) Background : Statin is the mainstay of treatment for the primary prevention of atherosclerotic cardiocerebrovascular diseases (CCVDs) in adults with hypercholesterolemia. This study aims to investigate the differences in effect on primary composite outcomes (CCVDs and CCVD-related deaths) among five statins in hypercholesterolemic individuals. (2) Methods : This retrospective study is based on the Korean National Health Insurance Service-National Health Screening Cohort. Participants, aged 40 to 69 years at baseline, were categorized into five statin-treated groups (pitavastatin, atorvastatin, rosuvastatin, simvastatin, and pravastatin) and two untreated groups (untreated hypercholesterolemia and no hypercholesterolemia). (3) Results : A total of 161,583 individuals was included. The median follow-up period was 8.2 years. Compared with the pitavastatin group, the hazard ratios (HRs; 95% confidence intervals (CIs)) for CCVDs and CCVD-related deaths of the atorvastatin, rosuvastatin, simvastatin, pravastatin, untreated hypercholesterolemia, and no-hypercholesterolemia groups were 0.969 (0.567–1.657), 0.988 (0.533–1.832), 0.862 (0.490–1.518), 0.906 (0.326–2.515), 2.665 (1.556–4.562), and 0.656 (0.388–1.110), respectively, in men and 1.124 (0.632–1.999), 1.119 (0.582–2.152), 1.324 (0.730–2.400), 1.023 (0.330–3.171), 2.650 (1.476–4.758), and 0.921 (0.522–1.625), respectively, in women, after being fully adjusted. (4) Conclusions : No significant differences among the five statins were observed, but there was an increased risk in untreated hypercholesterolemic individuals, for CCVDs and CCVDs-related deaths in individuals with hypercholesterolemia of either sex.

Keywords: HMG-CoA reductase inhibitors; pitavastatin; cardiovascular diseases; cerebrovascular diseases; hypercholesterolemia (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/17/6309/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/17/6309/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:17:p:6309-:d:406205

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().